We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prevalence of Psoriatic Arthritis Patients Achieving Minimal Disease Activity in Real-world Studies and Randomized Clinical Trials: Systematic Review with Metaanalysis.
- Authors
Zardin-Moraes, Mariele; Azeredo da Silva, André Luis Ferreira; Saldanha, Carla; Kohem, Charles Lubianca; Coates, Laura C.; Henrique, Lilian Rodrigues; Palominos, Penélope Esther; da Silva Chakr, Rafael Mendonça; da Silva, André Luis Ferreira Azeredo; Chakr, Rafael Mendonça da Silva
- Abstract
<bold>Objective: </bold>To estimate the frequency of patients with psoriatic arthritis (PsA) achieving minimal disease activity (MDA) status in real-world studies and randomized controlled trials (RCT).<bold>Methods: </bold>A systematic literature search for 2009-2017 was performed in PubMed, Embase, Cochrane Library, and LILACS. Study selection and data extraction were performed by 2 independent researchers. Random-effects single-arm metaanalyses were performed and heterogeneity was assessed using I2.<bold>Results: </bold>A total of 405 records were identified and 45 studies were analyzed: 39 (86.7%) observational studies and 6 (13.3%) RCT; they included 12,469 patients. The overall prevalence of MDA in cross-sectional studies was 35% (95% CI 30%-41%, I2 = 94%), varying from 17% (95% CI 7%-34%) in patients taking synthetic disease-modifying antirheumatic drugs (DMARD) to 57% (95% CI 41%-71%) in those taking biological DMARD. Prevalence of MDA in cohort studies increased with longer followup time, ranging from 25% (95% CI 15%-40%) with 3- to 4-month followup to 42% (95% CI 38%-45%) with > 24-month followup. Patients with PsA receiving biological DMARD in a real-world context and RCT had similar prevalence of MDA at 6-month followup: 30% (95% CI 21%-41%, I2 = 85%) versus 32% (95% CI 26%-39%, I2 = 79%), respectively.<bold>Conclusion: </bold>Patients with PsA included in real-world studies had similar prevalence of MDA compared to those in controlled clinical trials. This finding suggests that MDA is a useful treatment target for PsA in the real-world setting.
- Subjects
PSORIATIC arthritis; GENETICS of rheumatoid arthritis; AUTOIMMUNE diseases; RHEUMATOID arthritis risk factors; CLINICAL trials
- Publication
Journal of Rheumatology, 2020, Vol 47, Issue 6, p839
- ISSN
0315-162X
- Publication type
journal article
- DOI
10.3899/jrheum.190677